Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Spero Therapeutics (NASDAQ:SPRO) to a hold rating in a research report report published on Monday,Zacks reports.

SPRO has been the subject of a number of other research reports. HC Wainwright upped their price target on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday. Compass Point raised Spero Therapeutics to a “neutral” rating in a research report on Monday. Finally, Weiss Ratings upgraded Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock opened at $1.13 on Monday. Spero Therapeutics has a 1-year low of $1.08 and a 1-year high of $3.08. The company’s fifty day simple moving average is $1.32 and its 200-day simple moving average is $2.10. The stock has a market capitalization of $65.81 million, a PE ratio of 10.27 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. As a group, research analysts anticipate that Spero Therapeutics will post -0.58 EPS for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna Fundamental Investments LLC bought a new stake in Spero Therapeutics in the 2nd quarter valued at $36,000. Global Retirement Partners LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth $55,000. Intrepid Family Office LLC boosted its holdings in shares of Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after purchasing an additional 55,000 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Spero Therapeutics during the second quarter valued at about $632,000. Finally, BlackRock Inc. purchased a new position in shares of Spero Therapeutics during the second quarter valued at about $1,314,000. Institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.